Cargando...
Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics
Up to 30% of people with schizophrenia do not respond to two (or more) trials of dopaminergic antipsychotics. They are said to have treatment-resistant schizophrenia (TRS). Clozapine is still the only effective treatment for TRS, although it is underused in clinical practice. Initial use is delayed,...
Guardado en:
| Publicado en: | Pharmgenomics Pers Med |
|---|---|
| Autores principales: | , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Dove Medical Press
2016
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5106233/ https://ncbi.nlm.nih.gov/pubmed/27853387 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PGPM.S115741 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|